The Role of Imaging with Cardiac Computed Tomography in Cardio-Oncology Patients

Pitekova, Barbora; Ravi, Sriram; Shah, Shimoli; Mladosievičová, Beáta; Heitner, Stephen B.; Ferencik, Maros

doi:10.1007/s11886-016-0768-z

Cited by 7 publications

(2 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[236][237][238][239][240] Recently, CMR imaging 241,242 and cardiac CT 243 have been explored for their utility in evaluating cancer treatment-induced cardiotoxicity. Cardiac CT has an excellent diagnostic performance for the detection of subclinical atherosclerosis, coronary atherosclerotic plaque, and obstructive coronary artery disease, 243 while CMR has added value in characterizing myocardial remodeling. 241 Conceptually, left ventricular (LV) remodeling is defined in response to myocardial injury or overload through chamber dilation and/or hypertrophy.…”

Section: Advanced Non-nuclear Molecular Imaging Modalitiesmentioning

confidence: 99%

“…Among these techniques, 3D echocardiography strain rate/deformation imaging, metabolic imaging, and myocardial systolic velocities seem more sensitive and should facilitate the identification of patients with more subtle measures of cardiac function . Recently, CMR imaging and cardiac CT have been explored for their utility in evaluating cancer treatment‐induced cardiotoxicity. Cardiac CT has an excellent diagnostic performance for the detection of subclinical atherosclerosis, coronary atherosclerotic plaque, and obstructive coronary artery disease, while CMR has added value in characterizing myocardial remodeling .…”

Section: Caveats Challenges and Insights On The Diagnosis And Theramentioning

confidence: 99%

See 1 more Smart Citation

Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights

Zheng

Kros

2017

Medicinal Research Reviews

View full text Add to dashboard Cite

To date, five cancer treatment modalities have been defined. The three traditional modalities of cancer treatment are surgery, radiotherapy, and conventional chemotherapy, and the two modern modalities include molecularly targeted therapy (the fourth modality) and immunotherapy (the fifth modality). The cardiotoxicity associated with conventional chemotherapy and radiotherapy is well known. Similar adverse cardiac events are resurging with the fourth modality. Aside from the conventional and newer targeted agents, even the most newly developed, immune‐based therapeutic modalities of anticancer treatment (the fifth modality), e.g., immune checkpoint inhibitors and chimeric antigen receptor (CAR) T‐cell therapy, have unfortunately led to potentially lethal cardiotoxicity in patients. Cardiac complications represent unresolved and potentially life‐threatening conditions in cancer survivors, while effective clinical management remains quite challenging. As a consequence, morbidity and mortality related to cardiac complications now threaten to offset some favorable benefits of modern cancer treatments in cancer‐related survival, regardless of the oncologic prognosis. This review focuses on identifying critical research‐practice gaps, addressing real‐world challenges and pinpointing real‐time insights in general terms under the context of clinical cardiotoxicity induced by the fourth and fifth modalities of cancer treatment. The information ranges from basic science to clinical management in the field of cardio‐oncology and crosses the interface between oncology and onco‐pharmacology. The complexity of the ongoing clinical problem is addressed at different levels. A better understanding of these research‐practice gaps may advance research initiatives on the development of mechanism‐based diagnoses and treatments for the effective clinical management of cardiotoxicity.

show abstract